On the other hand, an implementation of insulin for a break-through therapy in type 2 diabetic patients may correct the resistance of glucagon-like peptide-1 (GLP-1) and of the glucose dependent insulinotropic peptide (GIP) alike, which are the other hormonal types of resistance characteristic of this diabetic population [29]. Here, GLP1R is linked to type 2 diabetes mellitus.